Innovation Pharmaceuticals Inc (OTCMKTS: IPIX) is spiking northbound after the Company reported it received additional data from a U.S. Regional Biocontainment Laboratory (RBL) collected during ongoing in vitro testing supporting Brilacidin as a potential treatment for SARS-CoV-2, the novel coronavirus responsible for COVID-19. In human lung epithelial cell line experiments performed at the RBL, Brilacidin in combination with Remdesivir, compared to Remdesivir-only treated conditions, showed a statistically significant and synergistic inhibition of SARS-CoV-2. Of particular note, overall viral load was reduced by 99.85 percent in one combination experiment, with remaining virus dropping to near undetectable levels.
This is big news for IPIX which is fast emerging as one of the most exciting stocks in small caps as Brilacidin as a treatemtn for coronavirus continues to gain serous traction. Brilacidin is being evaluated at a U.S. Regional Biocontainment Laboratory (RBL) and has consistently demonstrated robust in vitro antiviral properties against coronavirus. When a stock like IPIX heats up, investors pay attention; before it was trading as IPIX, CTIX was the darling of the bb’s all the way to $4.93 before the shorts led by Mako Research took it to the woodshed.
Innovation Pharmaceuticals Inc (OTCMKTS: IPIX) is a clinical stage pharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory and antibiotic applications. The Company owns the rights to numerous drug compounds, including Brilacidin, our lead drug in a new class of compounds called defensin-mimetics, and Kevetrin (thioureidobutyronitrile), our lead anti-cancer compound.
Brilacidin is being studied by the Company, as well as other independent researchers, as a potential therapeutic for the treatment of the novel coronavirus (SARS-CoV-2), which is responsible for COVID-19. Data from a leading U.S. Public Health Research Institute (PHRI) showed that Brilacidin appears to have primarily an extracellular mechanism of action, by disrupting viral integrity and blocking viral entry. In contrast, Remdesivir—currently authorized by the FDA for emergency use against COVID-19—has an intracellular mechanism of action, affecting viral replication post-infection. Exhibiting different but synergistic antiviral properties, these two drugs may be an especially potent drug combination in treating COVID-19. In other newly conducted lab testing at the RBL, Brilacidin was shown to inhibit SARS-CoV-2 in a human intestinal epithelial cell line and in primary fibroblast cells obtained from human donors. The Company has been informed by the RBL that it is nearing completion of its in vitro testing of Brilacidin against SARS-CoV-2 and will be submitting findings for peer-review publication. The publication will be solely focused on Brilacidin, with a pre-print made available.
To Find out the inside Scoop on IPIX Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
Earlier this month IPIX announced the publication of independent research, in Oncology Reports, a leading oncology journal, supporting the therapeutic potential of Kevetrin, the Company’s p53-modulating anti-cancer drug candidate, in treating Acute Myeloid Leukemia (AML). AML accounts for approximately one-quarter to one-third of all leukemias worldwide and has a 5-year survival rate of only 24 percent. In the recently published Kevetrin AML research, linked below, Kevetrin treatment was shown to arrest cell growth and cause cell death (apoptosis) in AML cells. Multiple p53 targets, several cellular processes and oncogenic pathways were also shown to be positively impacted by Kevetrin. Kevetrin was further shown to exhibit preferential cytotoxic activity against leukemia blast cells, while largely not affecting the immune microenvironment, supporting a less toxic drug profile. The researchers concluded: “These findings suggest that Kevetrin may be a promising therapeutic option for patients with both wild-type and TP53-mutant AML.”
Commenting on the data received from the U.S. Regional Biocontainment Laboratory (RBL) IPIX CEO Leo Ehrlich stated: “The Brilacidin and Remdesivir in vitro combination results are compelling. As we prepare to initiate our own clinical testing of Brilacidin for COVID-19 as a standalone therapy, given its consistent and robust antiviral activity, these latest test results indicate that combination trials with other drugs may be warranted. To that end, the company is pursuing grant opportunities with potential for larger, government-funded clinical trials. Such trials might include options for administration of Brilacidin in combination with Remdesivir, the world’s leading frontline COVID-19 treatment. It is exciting as we now rapidly transition from laboratory testing to the clinical testing of Brilacidin in hopes of treating COVID-19. Public reticence to use vaccines, alongside questions surrounding vaccine safety, efficacy, and timing of availability, further support the critical need for a promising drug like Brilacidin to emerge in the global fight against COVID-19.”
$IPIX Laboratory Testing of Brilacidin for COVID-19 in Combination with Remdesivir Reduces Viral Load by Nearly 100 Percenthttps://t.co/pDbjUHo6fg$JCPNQ $PFWIQ $DKNG $PASO $STHC $AREXQ $PCTL $QUTR $CBDD $RBII $ENZC $TSLA $NKLA $FBIO $IDEX $OPTI $TPTW $HNCKF $SFIN $VXRT $ZNGYQ
— Stock FX (@StockFXz) September 15, 2020
We have a Monster Pick Coming. Subscribe Right Now!
Currently running northbound with power IPIX is fast emerging as one of the most exciting stocks in small caps as Brilacidin continues to show significant progress as a treatment for coronavirus. Brilacidin is being evaluated at a U.S. Regional Biocontainment Laboratory (RBL) and has consistently demonstrated robust in vitro antiviral properties. According to newly received additional data from RBL, Brilacidin in combination with Remdesivir, compared to Remdesivir-only treated conditions, showed a statistically significant and synergistic inhibition of SARS-CoV-2. Of particular note, overall viral load was reduced by 99.85 percent in one combination experiment, with remaining virus dropping to near undetectable levels. If the results continue to show these kind of results, pressure will be intense to approve it for sale. We will be updating on IPIX when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with IPIX.
Sign Up now for our 100% FREE Penny Stock Newsletter
Disclosure: we hold no position in IPIX either long or short and we have not been compensated for this article.